Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart

Koki Takahashi1, Tomohiro Osanai, Takao Nakano

  • 1Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.

Heart and Vessels
|October 17, 2002
PubMed

Insights

Phosphodiesterase 3 and 4 (PDE3 and PDE4) gene expression and activity increase in salt-induced heart failure. This suggests PDEs contribute to the development and worsening of congestive heart failure (CHF).

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Pharmacology

Background:

  • Phosphodiesterase (PDE) expression varies in heart conditions, being downregulated in failing hearts and upregulated in hypertrophy.
  • Understanding PDE regulation in heart failure is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the time course of phosphodiesterase 3 and 4 (PDE3 and PDE4) gene expression and activity.
  • To determine the role of PDEs in salt-induced hypertension, left ventricular hypertrophy, and congestive heart failure (CHF).

Main Methods:

  • Dahl salt-sensitive (DS) and salt-resistant (DR) rats were fed an 8% NaCl diet.
  • PDE3 and PDE4 activity, mRNA expression, cardiac cyclic adenosine monophosphate, and plasma nitric oxide were measured at 11 and 18 weeks.

Main Results:

  • PDE4 activity was higher in DS rats at 11 weeks (hypertrophy stage).
  • At 18 weeks (CHF stage), both PDE3 and PDE4 activity and mRNA expression were elevated in DS rats compared to DR rats.
  • Cardiac cyclic adenosine monophosphate and plasma nitric oxide levels changed differentially over time in DS rats.

Conclusions:

  • PDE3 and PDE4 gene expression and activity are augmented during the hypertrophic and CHF stages in this salt-induced heart failure model.
  • Enhanced PDE3 and PDE4 activity appear to contribute to the development and exacerbation of CHF.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...